Cargando…
A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations
SIMPLE SUMMARY: Glioblastoma (GBM) is the most common and deadliest brain tumor. Currently, there is no successful treatment available for GBM patients. Different genes are mutated in GBM tumors, including the tumor suppressor p53 gene. Another important gene responsible for cellular homeostasis is...
Autores principales: | Afjei, Rayhaneh, Sadeghipour, Negar, Kumar, Sukumar Uday, Pandrala, Mallesh, Kumar, Vineet, Malhotra, Sanjay V., Massoud, Tarik F., Paulmurugan, Ramasamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775980/ https://www.ncbi.nlm.nih.gov/pubmed/36551609 http://dx.doi.org/10.3390/cancers14246120 |
Ejemplares similares
-
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models
por: Sadeghipour, Negar, et al.
Publicado: (2022) -
A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells
por: Paulmurugan, Ramasamy, et al.
Publicado: (2018) -
Comparison of cell-based assays to quantify treatment effects of anticancer drugs identifies a new application for Bodipy-L-cystine to measure apoptosis
por: Kumar, Nita, et al.
Publicado: (2018) -
Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model
por: Malhotra, Meenakshi, et al.
Publicado: (2018) -
Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
por: Kumar, Vineet, et al.
Publicado: (2019)